ScreenerHero
IXIIXICO plc
LSE · GB · Healthcare · Biotechnology · ixico.com
7.500GBP0.00%Mkt Cap: 21.06M $P/E: —

IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collectio…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap21.06M $
Enterprise Value7.48M $
Revenue (TTM)9.33M $
Gross Profit4.08M $
Net Income (TTM)-2.12M $
Revenue/Share0.1000 USD
Last Price7.500 GBP
Fiscal Year EndSep 2025
MR QuarterMar 2026
Employees79
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.15
PEG—
EV/EBITDA-2.19
EV/Revenue0.80
P/S2.41
P/B0.69
EPS (TTM)-0.02
EPS (Forward)-0.01
52W Range
6.26014% of range15.00
52W High15.00 GBP
52W Low6.260 GBP
Profitability
Gross Margin48.71%
Oper. Margin-31.43%
EBITDA Margin-36.67%
Profit Margin-25.27%
ROE-14.07%
ROA-11.93%
Growth
Revenue Growth23.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.29M $
CapEx (TTM)1.12M $
FCF Margin-43.73%
FCF Yield-19.37%
Net Debt-1.43M $
Net Debt/EBITDA0.42
Balance Sheet
Debt/Equity0.02
Current Ratio2.83
Quick Ratio2.83
Book Value/Sh0.1160 GBP
Cash/Share0.0180 GBP
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBP
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateSep 4, 2013
Analyst Consensus
Rating—
Target (Mean)26.00 GBP
Upside (mean)+246.7%
Target Range26.00 GBP – 26.00 GBP
# Analysts1
Ownership
Shares Out.218.97M
Float40.54M
Insiders4.89%
Institutions82.55%
Technical
SMA 508.303 (-9.7%)
SMA 2009.023 (-16.9%)
Beta0.11
S&P 52W Chg18.16%
Avg Vol (30d)70.26K
Avg Vol (10d)26.44K
Technical Indicators
RSI (14)32.2
MACD-0.2559
MACD Signal-0.2018
MACD Hist.-0.0540
BB Upper8.839 GBP
BB Middle7.994 GBP
BB Lower7.150 GBP
BB Width21.13%
ATR (14)0.6556 GBP
Vol Ratio (20d)0.05x